Sector News

Becton Dickinson to buy CareFusion for $12bn

October 8, 2014
Life sciences

Medical devices giant Becton Dickinson (BD) has agreed to buy automation and infection prevention specialist CareFusion for over $12 billion (£7.5 billion) in a mixture of shares and borrowed cash.

CareFusion develops technology for reducing drug dispensing errors by automation, and for preventing and detecting infections.

BD says that Carefusion’s products are complementary to its own ranges, and its distribution infrastructure will allow the merged company to increase global sales and cut supply chain costs.

The move follows other consolidation between major players in the medical devices segment, including Medtronic’s $43 billion purchase of Covidien in June.

Source: Chemistry World

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”